Phase II study of allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and fludarabine as conditioning regimen - IVBU1002(FB4): Phase II study of once daily ivBu+Flu

Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital0 个研究点目标入组 75 人开始时间: 2013年1月21日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients who have one of the following organ dysfunction 1) SPO2<90% by room air, %VC=<30% or FEV1.0%=<40% 2) sCr>2.0mg/dL 3) T-bil>2.0mg/dL 4) AST, ALT or ganma-GTP>3 x upper limit of normal range 5) Ejection fraction of left ventricle<40% by UCG (2) Patients with uncontrolled diabetes mellitus in spite of regular use of insulin (3) Patients with uncontrolled hypertension in spite of use of antihypertensive drugs (4) Patients who have active infection (5) Patients who are positive for TPHA, HBV surface antigen or anti-HCV antibody (6) Patients who are positive for anti-HTLV-I or anti-HIV antibody (7) Patients who are not evaluated to be able to survive more than 100 days after transplantation (8) Patients who have coinciding active malignancies (9) Patients who are pregnant or in the lactation period, and who are not able to, or not willing to prevent conception during the therapeutic period of this clinical trial (10) Patients who have psychiatric disorder (11) Patients who have prior hematopoietic stem cell transplantation (12) Patients who are considered as inappropriate to register by attending physicians

发起方

Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital